Table 1.
Demographic data of the parturients investigated and their newborns (median and 95% CI)
| Control group (n = 24) | Diabetes group (n = 11) | |||
|---|---|---|---|---|
| Parameters | PK + TD (n = 13) | TD (n = 11) | PK + TD (n = 10) | TD (n = 1) |
| Age (years) | 29.23 (25.96, 32.50) | 30.50 (27.23, 35.20) | 33.00 (28.41, 37.57) | 36.00 |
| Weight (kg) | 107.00 (88.81, 111.76) | 101.70 (91.60, 119.64) | 100.15 (92.08, 106.71) | 102.80 |
| BMI (kg m−2) | 39.91 (34.37, 41.85) | 39.51 (35.52, 43.62) | 38.42 (36.14, 41.79) | 42.30 |
| Gestational age (days) | 275.00 (267.66, 283.42) | 268.00 (261.80, 277.47) | 270.50 (268.06, 284.54) | 264.00 |
| Fasting glycaemia (mmol l−1) | 4.33 (3.67, 4.73) | 4.14 (3.27, 4.79) | 5.05*(4.38, 5.50) | 3.55 |
| 2 h glycaemia (OGTT 75-mmol l−1) | – | – | 7.83 (5.64, 10.19) | 6.33 |
| Glycated haemoglobin (%) | – | – | 5.20 (4.59, 6.11) | 5.30 |
| Systolic arterial pressure (mmHg)† | 140.00 (129.99, 148.78) | 140.00 (125.90, 157.19) | 140.00 (122.64, 161.58) | 135.00 |
| Systolic arterial pressure (mmHg)‡ | 135.50 (127.38, 150.78) | 124.00 (110.42, 134.15) | 120.00* (111.63, 123.7) | 130.00 |
| Diastolic arterial pressure (mmHg)† | 80.00 (58.90, 91.86) | 90.00 (80.33, 102.94) | 83.00 (69.19, 98.41) | 90.00 |
| Diastolic arterial pressure (mmHg)‡ | 81.00 (68.91, 92.59) | 68.00 (58.27, 72.87) | 55.00* (49.11, 76.00) | 90.00 |
| Heart rate (beats min−1)† | 76.00 (71.95, 87.69) | 82.00 (73.01, 92.99) | 84.00 (79.75, 88.91) | 80.00 |
| Heart rate (beats min−1)‡ | 80.00 (76.04, 84.84) | 70.00 (63.36, 76.07) | 77.00 (66.83, 83.61) | 72.00 |
| Associated pharmaceuticals | 1;2;3;4;5;6;7;8;9;10 | 1;2;3;4;5;6;8;10;11 | 1;2;3;4;5;6;8;10;12 | 4;5;6;8 |
| Newborn weight (g) | 3170.0 (2783.2, 3313.0) | 3345.0 (3096.5, 3986.0) | 3647.5*(3441.5, 3974.5) | 2780 |
| Newborn length (cm) | 48.50 (46.84, 50.09) | 49.00 (48.07, 50.83) | 50.50* (49.44, 51.66) | 46.50 |
†
Haemodynamic parameters measured before metoprolol administration;
‡
Haemodynamic parameters measured 2 h after metoprolol administration; PK + TD = parturients included in the pharmacokinetics and transplacental distribution study; TD = parturients included only in the transplacental distribution study; Associated pharmaceuticals: 1 methyldopa, 2 nifedipine, 3 hydralazine, 4 dipyrone, 5 oxytocin, 6 cefazolin, 7 dimethicone, 8 ferrous sulphate, 9 metronidazole, 10 misoprostol, 11 betamethasone, 12 furosemide; BMI: Body mass index;
*
Mann–Whitney test, P < 0.05 (PK + TD Control group vs. PK + TD diabetes group).